



CBD MED RESEARCH CORP

#810 – 675 W. Hastings Street, Vancouver, B.C., Canada V6B 1N2
Tel: 604-802-7551 • www.cbdmedresearch.com

January 3, 2017

CBD MED RESEARCH CORP. ("CBM" or the "Company")

TSX.V NEX Symbol: CBM.H

CBD MED Research Corp. Issues Early Warning Report

January 3, 2017: CBD MED Research Corp: Further to the Company's news release dated December 23, 2016 announcing the closing of the private placement, Gianni Maddalozzo purchased 950,000 units from the Company at a price of \$0.06 per unit, pursuant to the private placement. Prior to the closing of the private placement, Mr. Maddalozzo owned 118,808 shares of the Company. As a result of Mr. Maddalozzo's acquisition, he now owns 1,068,808 common shares and 950,000 share purchase warrants in the capital of the Company, representing approximately 12.91% of the Company's current issued and outstanding share capital on a post-conversion beneficial ownership basis.

On behalf of the Board of Directors,

CBD Med Research Corp.

"Gary F. Zak"

President, CEO

Email: gzak1@shaw.ca

Tel: 604-802-7551

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes certain statements that may be deemed "forward-looking statements". For more information on the Company and the risks and challenges of its business, investors should review the Company's annual filings that are available at www.sedar.com